Amgen layoffs, on the record
Every job cut, severance charge and restructuring Amgen reported in its annual reports, 2023 to 2025, quoted from the filings.
Job cuts, severance and restructuring
Our summaryCompany ran a restructuring plan that was started and substantially finished in 2023, with related expenses recorded in other operating expenses.
Word for word“Other operating expenses for 2023 primarily consisted of a net IPR&D intangible asset impairment charge for AMG 340 and expenses related to our restructuring plan that were both initiated and substantially completed in 2023.” 10-K for 2024
Our summaryCompany incurred expenses tied to cost-savings initiatives in 2024, recorded in other operating expenses.
Word for word“Other operating expenses for 2024 primarily consisted of impairment charges associated with IPR&D intangible assets related to our Teneobio acquisition in 2021 and expenses related to cost-savings initiatives incurred in 2024.” 10-K for 2024
Our summaryCompany recorded acquisition costs for the Horizon closing, including severance and other employee-related expenses.
Word for word“During the three months ended December 31, 2023, the Company incurred approximately $ 487 million of acquisition costs related to the closing of our Horizon acquisition, consisting of $ 167 million for share-based payments to settle non-vested equity awards attributable to post-combination services, severance and other employee-related expenses and $ 320 million for transaction costs.” 10-K for 2024
Our summaryAmgen reported expenses for cost-savings initiatives in 2024 and for a restructuring plan that was started and substantially completed in 2023, both included in other operating expenses.
Word for word“Other operating expenses for 2023 included a net IPR&D intangible asset impairment charge for AMG 340 and expenses related to our restructuring plan that were both initiated and substantially completed in 2023.” 10-K for 2025
| Fiscal year ended | Restructuring charges | Cash paid for restructuring |
|---|---|---|
| 2016-12-31 | $19 million | $117 million |
| 2017-12-31 | $79 million | $31 million |
| 2023-12-31 | $267 million | — |
Amgen has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Amgen’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-13. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.